{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T19:34:59Z","timestamp":1776627299252,"version":"3.51.2"},"reference-count":7,"publisher":"BMJ","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.p2766","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T10:45:18Z","timestamp":1700736318000},"page":"p2766","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Cystic fibrosis: What next for the \u201cwonder drug\u201d Kaftrio?"],"prefix":"10.1136","author":[{"given":"Jacqui","family":"Wise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"2023112306450678000_383.nov23_2.p2766.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1094"},{"key":"2023112306450678000_383.nov23_2.p2766.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6206"},{"key":"2023112306450678000_383.nov23_2.p2766.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2643"},{"key":"2023112306450678000_383.nov23_2.p2766.4","unstructured":"NHS England. \u201cMiracle\u201d cystic fibrosis treatment for children on the NHS. 12 Jan 2022. https:\/\/www.england.nhs.uk\/2022\/01\/miracle-cystic-fibrosis-treatment-for-children-on-the-nhs\/"},{"key":"2023112306450678000_383.nov23_2.p2766.5","unstructured":"Medicines and Healthcare Products Regulatory Agency. Cystic fibrosis drugs Kaftrio and Kalydeco licensed for patients aged two to five years old. 15 Nov 2023. https:\/\/www.gov.uk\/government\/news\/cystic-fibrosis-drugs-kaftrio-and-kalydeco-licensed-for-patients-aged-two-to-five-years-old"},{"key":"2023112306450678000_383.nov23_2.p2766.6","unstructured":"National Institute for Health and Care Excellence. Ivacaftor\u2013tezacaftor\u2013elexacaftor, tezacaftor\u2013ivacaftor and lumacaftor\u2013ivacaftor for treating cystic fibrosis [ID3834]. In development [GID-TA11187]. Expected publication 20 Mar 2024. https:\/\/www.nice.org.uk\/guidance\/GID-TA11187\/documents\/draft-guidance. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11187"},{"key":"2023112306450678000_383.nov23_2.p2766.7","unstructured":"Phipps A, Royce R. Kaftrio: parents fear loss of cystic fibrosis \u201cmiracle drug\u201d. BBC News 2023 Nov 17. https:\/\/www.bbc.co.uk\/news\/uk-england-leicestershire-67427900"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.p2766","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.p2766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T14:45:17Z","timestamp":1700750717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.p2766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":7,"alternative-id":["10.1136\/bmj.p2766"],"URL":"https:\/\/doi.org\/10.1136\/bmj.p2766","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}